Drug

Actinium AC-225 dotatate clinical trials

Also written RYZ101.

studies test it: 5
open now: 2
in phase 3: 1
first study started: 2022

How each study uses actinium AC-225 dotatate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the actinium AC-225 dotatate studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: Not in FDA's approval records
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

ACTINIUM AC-225 DOTATATE: 1

Development codes

RYZ101: 4

Other names

225Ac-Oxodotreotide: 1
225Ac-DOTATATE: 1

Studies by the year they started

5 studies that test it; most in 2022 (2)

Studies that test actinium AC-225 dotatate, by start year
Year	Studies
2022	2
2024	2
2025	1

By phase

A phase 1/2 study counts in both.

Phase 1: 4
Phase 2: 2
Phase 3: 1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Gastro-enteropancreatic neuroendocrine tumor: 1
Breast Neoplasms: 1
Meningioma: 1
Multiple Myeloma: 1

Who runs them

Industry 3 · Other 2

RayzeBio, Inc. (3) · Joshua Palmer (1) · Jules Bordet Institute (1)

Related medicines

As reviewed, each with the page that says it.

One of Radiopharmaceuticals source

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3, 1 in phase 3

Studies that test actinium AC-225 dotatate, phase 3 first.

Dec 2026Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyPhase 3 · RayzeBio, Inc.
Dec 2026RYZ101 for the Treatment of Progressive or Recurrent Intracranial MeningiomaPhase 1/2 · Joshua Palmer
Jul 2027Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLCPhase 1 · RayzeBio, Inc.

Studies

Open first, then newest update. How each study uses actinium AC-225 dotatate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 5

Codes

What other systems call actinium AC-225 dotatate · ClinicalTrials.gg INT017929

UNII (FDA) SP9ZNW6WAKACTINIUM AC-225 DOTATATEOne source FDA
NCI Thesaurus C189915Actinium Ac 225 DOTATATE RYZ101One source FDA

System	Code	Name there	Checked by
UNII (FDA)	SP9ZNW6WAK	ACTINIUM AC-225 DOTATATE	One source FDA
NCI Thesaurus	C189915	Actinium Ac 225 DOTATATE RYZ101	One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.